Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy
Open Access
Abstract
Resistance to immune checkpoint blockade therapy has spurred the development of novel combinations of drugs tailored to specific cancer types, including non-inflamed tumors with low T-cell infiltration. Cancer vaccines can potentially be utilized as part of these combination immunotherapies to enhance antitumor efficacy through the expansion of tumor-reactive T cells. Utilizing murine models of colon and mammary carcinoma, here we investigated the effect of adding a recombinant adenovirus-based vaccine targeting tumor-associated antigens with an IL-15 super agonist adjuvant to a multimodal regimen consisting of a bifunctional anti-PD-L1/TGF-βRII agent along with a CXCR1/2 inhibitor. We demonstrate that the addition of vaccine induced a greater tumor infiltration with T cells highly positive for markers of proliferation and cytotoxicity. In addition to this enhancement of cytotoxic T cells, combination therapy showed a restructured tumor microenvironment with reduced Tregs and CD11b+Ly6G+ myeloid cells. Tumor-infiltrating immune cells exhibited an upregulation of gene signatures characteristic of a Th1 response and presented with a more diverse T-cell receptor (TCR) repertoire. These results provide the rationale for the addition of vaccine-to-immune checkpoint blockade-based therapies being tested in the clinic.Keywords
Funding Information
- Intramural Research Program, Center for Cancer Research, NCI, NIH (n/a)
- Cooperative Research and Development Agreement with EMD Serono (n/a)
- Cooperative Research and Development Agreement with Syntrix Pharmaceuticals (n/a)
- Cooperative Research and Development Agreement with ImmunityBio (n/a)
This publication has 40 references indexed in Scilit:
- IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomasOncotarget, 2016
- Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor EradicationCancer Immunology Research, 2016
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockadeScience Translational Medicine, 2015
- Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic ProcessCancer Research, 2014
- Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian CancerCancer Research, 2013
- Combination immunotherapy approachesAnnals of Oncology, 2012
- IL-8 Signaling Plays a Critical Role in the Epithelial–Mesenchymal Transition of Human Carcinoma CellsCancer Research, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: Evaluation of CEA-based cancer vaccinesMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005